Roche posted a 7% increase in 2025 Group sales at constant exchange rates, with Pharmaceuticals up 9% and Diagnostics up 2%, alongside a 13% rise in core operating profit. The year delivered two approvals with immediate practice implications—subcutaneous Lunsumio in follicular lymphoma in the US and EU and Gazyva/Gazyvaro for lupus nephritis in the EU—plus late-stage wins that reset expectations in multiple sclerosis and ER-positive breast cancer. Roche also advanced 10 molecules into Phase III, reported positive Phase II data for CT-388 in obesity, completed the tender offer for 89bio, proposed a 39th consecutive dividend increase, and guided to mid-single-digit sales growth and high-single-digit core EPS growth in 2026.
The through line is strategic: Roche is rebuilding growth on three planks—convenience-first oncology, neuroimmunology durability, and a credible cardiometabolic entry—while absorbing price pressure in Diagnostics and biosimilar erosion in legacy oncology. The question for competitors and payers is whether the company can convert these clinical signals into durable, access-friendly market positions before the window narrows.
Subcutaneous Lunsumio compresses administration to about a minute, moving bispecifics closer to an outpatient, community-oncology reality. If adoption follows, this could shift site-of-care economics, reduce infusion capacity constraints, and recalibrate value frameworks that increasingly price convenience and care efficiency. Gazyva’s expansion into lupus nephritis, with additional positive data in systemic lupus erythematosus and pediatric idiopathic nephrotic syndrome, pushes Roche deeper into reno-immunology, a space primed for payer scrutiny but hungry for options that reduce steroid reliance and delay organ damage. For hematology-oncology, sustained momentum from Ocrevus, Hemlibra, Vabysmo, Phesgo, and Polivy suggests Roche is defending share by making administration simpler and regimens less chemotherapy-dependent, even as Perjeta and Actemra face conversion and biosimilar headwinds.
The most disruptive readouts may come from neuro and metabolic disease. Fenebrutinib’s positive Phase III results in both relapsing and primary progressive MS signal a franchise hedge and a potential class-defining moment for BTK inhibitors. It invites planning assumptions about label breadth, safety, and sequencing against Ocrevus, with the commercial calculus of internal cannibalization versus external defense. In breast cancer, giredestrant’s adjuvant benefit positions an oral SERD to reset endocrine therapy in ER-positive early disease for the first time in two decades, raising immediate imperatives for medical education, diagnostics alignment, and extended follow-up to support widespread adoption.
CT-388’s 22.5% placebo-adjusted weight loss at 48 weeks puts Roche on the cardiometabolic map, but late-mover realities loom. The 89bio acquisition underscores a portfolio approach to metabolic liver and obesity-adjacent pathology, yet payer dynamics, supply scaling, and combination strategies will determine whether Roche can carve a durable niche in a market dominated by incumbent GLP-1 players. Diagnostics remains a counterweight: new CE-marked tests in dengue, vaginitis, and antibiotic monitoring, plus a point-of-care Bordetella panel, align with decentralization and antimicrobial stewardship, even as China’s pricing reforms compress margins and force sharper focus on automation and throughput.
For Commercial and Medical Affairs leaders, the near-term priority is execution: accelerate subcutaneous and chemo-free pathways, prepare MS treatment algorithms for BTK entry, build the outcomes and adherence evidence base for an oral SERD in early breast cancer, and pre-wire payer narratives that quantify site-of-care savings and long-term disease modification. The strategic test is whether Roche can translate convenience, earlier intervention, and systems-level efficiency into contracting leverage and real-world advantage before competitors land their next wave. The next 12 months will reveal if this is a diversified growth reset or a crowded race to the same endpoints.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
